Skandinaviska Enskilda Banken (SEB)’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-9,041	Closed	-$970K	–	990
2023 Q1	$970K	Sell	9,041 -389	-4%	-$44.8K	0.01%	693
2022 Q4	$1.04M	Buy	+9,430	New	+$611K	0.01%	661

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s RXDX Position: Q2 2023 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 9,041 shares — an estimated $970K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $1.04M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Skandinaviska Enskilda Banken (SEB) reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Skandinaviska Enskilda Banken (SEB) sold 9,041 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $970K.
Skandinaviska Enskilda Banken (SEB) first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Skandinaviska Enskilda Banken (SEB)'s Prometheus Biosciences, Inc. Common Stock position peaked at $1.04M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q2 2023, filed 7 Aug 2023.